Humoral immune response as predictor of recurrence in Clostridium difficile infection

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages 1323-1328

  Bauer, M P ^a   Nibbering, P H ^a   Poxton, I R ^b   Kuijper, E J ^a   van Dissel, J T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Clostridium difficile; Antibodies; IgA; IgG; Recurrence; Toxins

Indexed keywords

CLOSTRIDIUM DIFFICILE;

BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

AGED; BLOOD; CELL SURVIVAL; CLOSTRIDIUM INFECTIONS; COHORT ANALYSIS; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; MALE; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CELL SURVIVAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS;

EID: 84920269708     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12769     Document Type: Article

References (19)

1. Carroll KC, Bartlett JG. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol 2011; 65: 501-521.
2. Aronsson B, Granstrom M, Mollby R, Nord CE. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985; 13: 97-101.
3. Drudy D, Calabi E, Kyne L et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 2004; 41: 237-242.
4. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 1992; 166: 1287-1294.
5. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-397.
6. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-193.
7. Leav BA, Blair B, Leney M et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28: 965-969.
8. Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993; 16(suppl 4): S239-S244.
9. Sanchez-Hurtado K, Corretge M, Mutlu E, McIlhagger R, Starr JM, Poxton IR. Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls. J Med Microbiol 2008; 57: 717-724.
10. Solomon K, Martin AJ, O'Donoghue C et al. Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses. J Med Microbiol 2013; 62: 1453-1460.
11. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384-389.
12. Numan SC, Veldkamp P, Kuijper EJ, van den Berg RJ, van Dissel JT. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007; 56: 888-889.
13. Young KW, Munro IC, Taylor SL, Veldkamp P, van Dissel JT. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile. Regul Toxicol Pharmacol 2007; 47: 317-326.
14. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
15. Bidet P, Lalande V, Salauze B et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 2000; 38: 2484-2487.
16. Sanchez-Hurtado K, Poxton IR. Enhancement of the cytotoxic activity of Clostridium difficile toxin A by surface-associated antigens. J Med Microbiol 2008; 57: 739-744.
17. Hancock IC, Poxton IR. Chapter 4, separation and purification of surface components in bacterial cell surface techniques. Chichester: Wiley, 1988; 73-75.
18. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307.
19. Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.